These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 24816443)

  • 1. Polyglutamine (PolyQ) diseases: genetics to treatments.
    Fan HC; Ho LI; Chi CS; Chen SJ; Peng GS; Chan TM; Lin SZ; Harn HJ
    Cell Transplant; 2014; 23(4-5):441-58. PubMed ID: 24816443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Expanding Clinical Universe of Polyglutamine Disease.
    Huang S; Zhu S; Li XJ; Li S
    Neuroscientist; 2019 Oct; 25(5):512-520. PubMed ID: 30614396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy and Polyglutamine Disease.
    Ren H; Hao Z; Wang G
    Adv Exp Med Biol; 2020; 1207():149-161. PubMed ID: 32671744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased aggregation of polyleucine compared with that of polyglutamine in dentatorubral-pallidoluysian atrophy protein.
    Suzuki Y; Jin C; Yazawa I
    Neurosci Lett; 2013 Sep; 552():156-61. PubMed ID: 23933208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machado-Joseph disease and other rare spinocerebellar ataxias.
    Matilla-Dueñas A
    Adv Exp Med Biol; 2012; 724():172-88. PubMed ID: 22411243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.
    Tenchov R; Sasso JM; Zhou QA
    ACS Chem Neurosci; 2024 Aug; 15(15):2665-2694. PubMed ID: 38996083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studying polyglutamine diseases in Drosophila.
    Xu Z; Tito AJ; Rui YN; Zhang S
    Exp Neurol; 2015 Dec; 274(Pt A):25-41. PubMed ID: 26257024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
    Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of SCA3 and implications for other polyglutamine diseases.
    McLoughlin HS; Moore LR; Paulson HL
    Neurobiol Dis; 2020 Feb; 134():104635. PubMed ID: 31669734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A peptidylic inhibitor for neutralizing expanded
    Zhang Q; Chen ZS; An Y; Liu H; Hou Y; Li W; Lau KF; Koon AC; Ngo JCK; Chan HYE
    RNA; 2018 Apr; 24(4):486-498. PubMed ID: 29295891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell death in polyglutamine diseases.
    Evert BO; Wüllner U; Klockgether T
    Cell Tissue Res; 2000 Jul; 301(1):189-204. PubMed ID: 10928291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation.
    Mangiarini L; Sathasivam K; Mahal A; Mott R; Seller M; Bates GP
    Nat Genet; 1997 Feb; 15(2):197-200. PubMed ID: 9020849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The advances in research on phosphorylation of polyglutamine disease].
    Zhou YF; Jiang H; Tang JG; Tang BS
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):414-7. PubMed ID: 18683139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases.
    Yamada M; Tan CF; Inenaga C; Tsuji S; Takahashi H
    Neuropathol Appl Neurobiol; 2004 Dec; 30(6):665-75. PubMed ID: 15541006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases.
    Lee LKC; Leong LI; Liu Y; Luo M; Chan HYE; Choi CHJ
    Mol Pharm; 2021 Feb; 18(2):610-626. PubMed ID: 32584043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential pattern in tissue-specific somatic mosaicism of expanded CAG trinucleotide repeats in dentatorubral-pallidoluysian atrophy, Machado-Joseph disease, and X-linked recessive spinal and bulbar muscular atrophy.
    Tanaka F; Sobue G; Doyu M; Ito Y; Yamamoto M; Shimada N; Yamamoto K; Riku S; Hshizume Y; Mitsuma T
    J Neurol Sci; 1996 Jan; 135(1):43-50. PubMed ID: 8926495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Triplet repeat disease, with particular emphasis of spinal and bulbar muscular atrophy (SBMA)].
    Sobue G
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1193-5. PubMed ID: 11464455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.
    Xiang C; Zhang S; Dong X; Ma S; Cong S
    Front Mol Neurosci; 2018; 11():153. PubMed ID: 29867345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations.
    Wanker EE
    Biol Chem; 2000; 381(9-10):937-42. PubMed ID: 11076024
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.